Michelle Renee Griffin Sells 6,000 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Director Michelle Renee Griffin sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $47.69, for a total value of $286,140.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $286,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
ADPT stock opened at $46.40 on Friday. The firm has a 50 day moving average of $49.50 and a 200-day moving average of $43.40. The firm has a market capitalization of $6.35 billion, a P/E ratio of -48.84 and a beta of 0.27. Adaptive Biotechnologies Co. has a 12 month low of $15.19 and a 12 month high of $54.20.
Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Sunday, November 15th. The company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. The firm had revenue of $26.30 million during the quarter, compared to the consensus estimate of $23.58 million. Adaptive Biotechnologies had a negative net margin of 132.32% and a negative return on equity of 20.15%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm earned ($0.11) EPS. Analysts anticipate that Adaptive Biotechnologies Co. will post -1.08 EPS for the current fiscal year.
Several analysts have issued reports on ADPT shares. William Blair restated an “outperform” rating on shares of Adaptive Biotechnologies in a research note on Tuesday, August 11th. BTIG Research upped their price objective on shares of Adaptive Biotechnologies from $60.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, November 12th. Morgan Stanley lifted their target price on shares of Adaptive Biotechnologies from $42.00 to $46.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 11th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and set a $60.00 price target (up from $50.00) on shares of Adaptive Biotechnologies in a research note on Wednesday, November 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $54.67.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals.
Read More: Dead Cat Bounce
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.